APA (7th ed.) Citation

Brown, S., Everett, C. C., Naraghi, K., Davies, C., Dawkins, B., Hulme, C., . . . Buch, M. H. (2018). Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: The SWITCH RCT. Health technology assessment (Winchester, England), 22(34), 1-280. https://doi.org/10.3310/hta22340

Chicago Style (17th ed.) Citation

Brown, Sarah, et al. "Alternative Tumour Necrosis Factor Inhibitors (TNFi) or Abatacept or Rituximab Following Failure of Initial TNFi in Rheumatoid Arthritis: The SWITCH RCT." Health Technology Assessment (Winchester, England) 22, no. 34 (2018): 1-280. https://doi.org/10.3310/hta22340.

MLA (9th ed.) Citation

Brown, Sarah, et al. "Alternative Tumour Necrosis Factor Inhibitors (TNFi) or Abatacept or Rituximab Following Failure of Initial TNFi in Rheumatoid Arthritis: The SWITCH RCT." Health Technology Assessment (Winchester, England), vol. 22, no. 34, 2018, pp. 1-280, https://doi.org/10.3310/hta22340.